PCSK9-mediated LDL receptor degradation (WP2846)

Homo sapiens

Open in new tab Open in NDEx Open in Newt (SBGN)
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads
Exogenously, circulating PCSK9 (Proprotein convertase subtilisin/kexin type 9) protein binds to LDLR (LDL receptor). Once internalized into the liver cell, the PCSK9 protein directs the LDLR to the lysosome for degradation. Intrinsically, PCSK9, which is secreted from the Golgi apparatus, binds the LDLR before it reaches the cell surface, leading it to lysosomal degradation. However, the precise mechanisms by which the intrinsic degradation pathway operates are still unknown. Abbreviations: LDLR, LDL receptor; PCSK9, proprotein convertase subtilisin/kexin type 9.

Authors

Susan Coort , Friederike Ehrhart , Chris Evelo , Alex Pico , and Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Annotations

Pathway Ontology

lipoprotein metabolic pathway cholesterol metabolic pathway

Cell Type Ontology

hepatocyte

Participants
Query Drugst.One

Label Type Compact URI Comment
LDL cholesterol Metabolite chebi:47774
LDLR GeneProduct ensembl:ENSG00000130164
PCSK9 GeneProduct ensembl:ENSG00000169174

References

  1. Pharmacological strategies for lowering LDL cholesterol: statins and beyond. Brautbar A, Ballantyne CM. Nat Rev Cardiol. 2011 May;8(5):253–65. PubMed Europe PMC Scholia